GlobalData. Colorectal Cancer: Epidemiology Forecast to 2028. 2019. Contract No.: GDHCER220-19.

Norway CRo. Cancer in Norway 2018—Cancer incidence, mortality, survival and prevalence in Norway. Oslo; 2019. Report No.: 0806-3621.

Crooke H, Kobayashi M, Mitchell B, Nwokeji E, Laurie M, Kamble S, et al. Estimating 1-and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.36.4_suppl.587.

Article  Google Scholar 

Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. AJCC cancer staging manual. New York: Springer; 2010.

Google Scholar 

Osterman E, Glimelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum. 2018;61(9):1016–25.

Article  PubMed  Google Scholar 

Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA: Cancer J Clin. 2019;69(2):127–57.

PubMed  Google Scholar 

Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14(1):1–7.

Article  Google Scholar 

Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci. 2017;18(1):107.

Article  PubMed  PubMed Central  Google Scholar 

Lyu H, Xu T, Brotman D, Mayer-Blackwell B, Cooper M, Daniel M, et al. Overtreatment in the united states. PLoS ONE. 2017;12(9): e0181970.

Article  PubMed  PubMed Central  Google Scholar 

Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology. 2019;28(7):1367–80.

Article  PubMed  PubMed Central  Google Scholar 

Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. 2016.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.

Article  PubMed  Google Scholar 

Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305.

Article  PubMed  Google Scholar 

Team O. The Oncotype® DX Breast Recurrence Score.

Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liestøl K, Maddison J, et al. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet. 2020;395(10221):350–60.

Article  CAS  PubMed  Google Scholar 

Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355–71.

Article  PubMed  Google Scholar 

Guidelines for the submission of documentation for single technology assessments (STAs) of medical devices and diagnostic interventions. In: Health NIoP, editor. 2020.

Seo MK, Strong M. A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper. PharmacoEconomics. 2021;1–9.

Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2023;21:1–13.

Google Scholar 

Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(11):1543–57.

Article  CAS  PubMed  Google Scholar 

Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data [Internet]. 2013.

Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 2015;35(2):255–65.

Article  PubMed  Google Scholar 

StatBank. Statistics Norway Mortality Tables. 2019. https://www.ssb.no/en/statbank/table/07902.

Felleskatalogen [The Norwegian Medicines Catalog]: Felleskatalog [The Norwegian Medicines Catalog]; 2020: https://www.felleskatalogen.no/medisin.

DCTD N, NIH, DHHS. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006.

Capecitabine Accord Felleskatalog2020: https://www.felleskatalogen.no/medisin/capecitabine-accord-accord-586441.

Oxaliplatin Fresenius Kabi Felleskatalog2019: https://www.felleskatalogen.no/medisin/oxaliplatin-fresenius-kabi-fresenius-kabi-568997.

DRG-systemet [DRG-system]. In: Health] HNDo, editor. Oslo: Helsedirektoratet; 2020.

Joranger P, Nesbakken A, Sorbye H, Hoff G, Oshaug A, Aas E. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. Eur J Health Econ. 2020;21(3):321–34.

Article  PubMed  Google Scholar 

Bjørnelv GMW, Edwin B, Fretland ÅA, Deb P, Aas E. Till death do us part: the effect of marital status on health care utilization and costs at end-of-life. A register study on all colorectal cancer decedents in Norway between 2009 and 2013. BMC Health Serv Res. 2020;20(1):115.

Article  PubMed  PubMed Central  Google Scholar 

Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294–303.

Article  CAS  PubMed  Google Scholar 

Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102.

Article  CAS  PubMed  Google Scholar 

Magnussen J, Aaserud M, Granaas T, Magelssen M, Syse A, Celius E. På ramme alvor-Alvorlighet og prioritering. Department of Health (p. 71). English summary available from: https://www.regjeringen.no/contentassets/d5da48ca5d1a4b128c72fc5daa3b4fd8/summary_the_magnussen_report_on_severity.pdf. 2015.

Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95–104.

Article  CAS  PubMed  Google Scholar 

Hornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value in Health. 2012;15(8):1014–21.

Article  PubMed  Google Scholar 

Jongeneel G, Greuter MJ, van Erning FN, Koopman M, Vink GR, Punt CJ, Coupé VM. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Ther Adv Gastroenterol. 2021;14:1756284821995715.

Article  CAS  Google Scholar 

Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, et al. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014;32:1231–43.

Article  PubMed  PubMed Central  Google Scholar 

To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39(8):953–64.

Article  PubMed  Google Scholar 

Alarid-Escudero F, Schrag D, Kuntz KM. CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: an exploratory cost-effectiveness analysis. Value in Health. 2022;25(3):409–18.

Article  PubMed  Google Scholar 

Kleppe A, Skrede O-J, De Raedt S, Hveem TS, Askautrud HA, Jacobsen JE, et al. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. Lancet Oncol. 2022;23(9):1221–32.

Article  CAS  PubMed  Google Scholar 

Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess (Winchester, England). 2004;8(5):iii–143.

Google Scholar